Trial Profile
A Phase I Study Using Most Closely HLA-matched Adenovirus-specific T Lymphocytes for the Treatment of Adenovirus Infections Post-allogeneic Stem Cell Transplant(VIRALYM-A)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 09 Jul 2021
Price :
$35
*
At a glance
- Drugs Adenovirus specific T cells ViraCyte (Primary)
- Indications Adenovirus infections
- Focus Adverse reactions
- Acronyms VIRALYM-A
- Sponsors AlloVir
- 19 Jul 2018 Status changed from recruiting to withdrawn prior to enrolment.
- 18 Dec 2017 Status changed from not yet recruiting to recruiting.
- 14 Dec 2017 Planned initiation date changed from 1 Dec 2017 to 1 Jan 2018.